Compound Profiles
Cyclic Glycine-Proline
IGF-1 Bioavailability Regulator & Neuroprotective Peptide
Competes with IGF-1 for IGFBP-3 binding, normalizing bioavailable IGF-1 levels. Acts as positive allosteric modulator of AMPA and GABA-A receptors.
Tesamorelin
GHRH Analog | Visceral Fat Reduction
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Cyclic Glycine-Proline with Tesamorelin?
Yes, but with caution. Both Cyclic Glycine-Proline and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is Cyclic Glycine-Proline and Tesamorelin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: insulin disrupting. Monitor accordingly.
What are the interactions between Cyclic Glycine-Proline and Tesamorelin?
Both Cyclic Glycine-Proline and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time Cyclic Glycine-Proline and Tesamorelin?
Cyclic Glycine-Proline has a half-life of Extended stability (more stable than linear GPE precursor) and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.